论文部分内容阅读
目的 :比较急性脑梗死早期二种扩溶剂的疗效。方法 :对发病 4 8小时以内 2 77例急性脑梗死患者选择了二种不同的血液稀释剂治疗 ,低分子右旋糖酐组 ( 1 64例 )和羟乙基淀粉组 ( 1 1 3例 )。结果 :低分子右旋糖酐组疗效较羟乙基淀粉组差 P<0 .0 5,原因可能是在急性脑梗死患者中有部分患者糖耐量受损 ,在输注含 6%葡萄糖的低分子右旋糖酐时引起一过性血糖升高致缺血脑损害加重。结论 :提出在急性脑梗死发病 4 8小时内选择血液稀释疗法时应尽量避免使用低分子右旋糖酐而用羟乙基淀粉代替。
Objective: To compare the efficacy of two kinds of solvent-dissolving agents in early stage of acute cerebral infarction. METHODS: Two different blood thinner treatments, a low molecular weight dextran group (1 64), and a hydroxyethyl starch group (113) were enrolled in 2 of 77 patients with acute cerebral infarction within 48 hours of onset. Results: The therapeutic effect of low molecular weight dextran group was lower than that of hydroxyethyl starch group (P <0.05). The reason may be that some patients with impaired glucose tolerance were impaired in patients with acute cerebral infarction. When low molecular weight dextran with 6% glucose was infused Caused by an increase in blood sugar caused by increased ischemic brain damage. Conclusion: It is suggested that the use of hydroxyethyl starch instead of low molecular weight dextran should be avoided when selecting hemodilution therapy within 48 hours after the onset of acute cerebral infarction.